Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
LEXINGTON, Mass., May 25, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a poster describing the Phase 1 trial of CA-170, an oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in the treatment of patients with advanced solid tumors or lymphomas at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from June 2-6 in Chicago.
In addition, researchers from the Dana-Farber Cancer Institute and Boston Children’s Hospital will be presenting information on an investigator-initiated Phase 1 multicenter trial using CUDC-907, Curis’ proprietary drug candidate, to treat children and young adults with relapsed or refractory solid tumors, CNS tumors and lymphoma.
Additional information on the presentations can be found below and can be accessed at www.am.asco.org.
CA-170 Poster Presentation:
| Date/Time: | Monday, June 5, 8 AM — 11:30 AM CDT |
| Abstract Number: | TPS3099 |
| Presentation Title: | Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas |
CUDC-907 Poster Presentation:
| Date/Time: | Sunday, June 4, 8 AM — 11:30 AM CDT |
| Abstract Number: | TPS10576 |
| Presentation Title: | Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma |
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
